RVNC News and Press, Revance Therapeutics Inc. From 04/06/21

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking ...

Revance Therapeutics (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place from April 17-22, 2021. Revance...

Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Fortune has recognized Revance on its 2021 Best Workplaces in Health Care & Biopharma™ list. Revance ranked No. 8 in the biopharma category. ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will participate in fireside chats at the Cowen 41 st Annual Vir...

— Data validated efficacy and safety and informs dosing strategy for Phase 3 program — Achieved key co-primary endpoint on efficacy, with 500U dose demonstrating statistically significant difference from placebo in the Modified Ashworth Score (MAS) improvement fr...

Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million Exited 2020 with over $200 million in annualized HintMD processi...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of accomplished biotech and pharmaceutical executive, Olivia C. Ware, and fintech and payments thought leader and entrepreneur, C...

Conference Call Scheduled for Monday, February 22, 2021 at 4:30 p.m. ET. Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year 2...

- Data from an open-label Phase 2 study of the treatment of upper facial lines with DaxibotulinumtoxinA for Injection highlighted – - Secondary analysis results from SAKURA, the largest Phase 3 aesthetic neuromodulator clinical program ever conducted for the treatment o...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the release of its inaugural ESG Report, which details the company’s commitments and efforts to build strong corporate governance, and ope...